These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

732 related items for PubMed ID: 19262226

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
    Smebye ML, Iversen EK, Høieggen A, Flaa A, Os I, Kjeldsen SE, Olsen MH, Chattopadhyay A, Hille DA, Lyle PA, Devereux RB, Dahlöf B.
    Am J Cardiol; 2007 Sep 01; 100(5):855-9. PubMed ID: 17719333
    [Abstract] [Full Text] [Related]

  • 23. In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
    Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahlöf B, Nieminen MS, Olsen MH, Okin PM, Palmieri V, Rokkedal JE, Devereux RB.
    Blood Press; 2010 Jun 01; 19(3):169-75. PubMed ID: 20438307
    [Abstract] [Full Text] [Related]

  • 24. Long-term plasma catecholamines in patients with hypertension and left ventricular hypertrophy treated with losartan or atenolol: ICARUS, a LIFE substudy.
    Fossum E, Olsen MH, Høieggen A, Wachtell K, Reims HM, Ibsen H, Julius S, Kjeldsen SE.
    J Hum Hypertens; 2004 Jun 01; 18(6):375-80. PubMed ID: 15057253
    [Abstract] [Full Text] [Related]

  • 25. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
    Okin PM.
    J Electrocardiol; 2009 Jun 01; 42(6):584-8. PubMed ID: 19631946
    [Abstract] [Full Text] [Related]

  • 26. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Dahlöf B, Burke TA, Krobot K, Carides GW, Edelman JM, Devereux RB, Diener HC.
    J Hum Hypertens; 2004 Jun 01; 18(6):367-73. PubMed ID: 15029217
    [Abstract] [Full Text] [Related]

  • 27. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
    Fossum E, Moan A, Kjeldsen SE, Devereux RB, Julius S, Snapinn SM, Edelman JM, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Dahlöf B, LIFE Study Group.
    J Am Coll Cardiol; 2005 Sep 06; 46(5):770-5. PubMed ID: 16139123
    [Abstract] [Full Text] [Related]

  • 28. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
    Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B, Losartan Intervention for Endpoint reduction in hypertension Study Investigations.
    Circulation; 2003 Aug 12; 108(6):684-90. PubMed ID: 12885747
    [Abstract] [Full Text] [Related]

  • 29. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
    Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K.
    Circulation; 2007 Aug 14; 116(7):700-5. PubMed ID: 17664372
    [Abstract] [Full Text] [Related]

  • 30. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
    de Simone G, Wachtell K, Palmieri V, Hille DA, Beevers G, Dahlöf B, de Faire U, Fyhrquist F, Ibsen H, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Devereux RB.
    Circulation; 2005 Apr 19; 111(15):1924-31. PubMed ID: 15837945
    [Abstract] [Full Text] [Related]

  • 31. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
    Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, Kjeldsen SE, Wachtell K.
    J Hum Hypertens; 2011 Mar 19; 25(3):178-85. PubMed ID: 20505749
    [Abstract] [Full Text] [Related]

  • 32. [Treatment of hypertension in patients with left ventricular hypertrophy].
    Omvik P, Bratland B, Gerhardsen G, Gisholt K, Risanger T, Smedsrud T, Kjeldsen SE.
    Tidsskr Nor Laegeforen; 2004 Mar 18; 124(6):788-91. PubMed ID: 15039810
    [Abstract] [Full Text] [Related]

  • 33. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.
    Am J Hypertens; 1997 Jul 18; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [Abstract] [Full Text] [Related]

  • 34. Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention for Endpoint reduction in hypertension (LIFE) study.
    McInnes G, Burke TA, Carides G.
    J Hum Hypertens; 2006 Jan 18; 20(1):51-8. PubMed ID: 16357874
    [Abstract] [Full Text] [Related]

  • 35. Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
    Egan B, Gleim G, Panish J.
    Curr Med Res Opin; 2004 Dec 18; 20(12):1909-17. PubMed ID: 15701209
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study].
    Ibsen H, Lindholm LH, Pedersen OL, Dahlöf B, Kjeldsen S.
    Ugeskr Laeger; 2003 Jan 27; 165(5):459-62. PubMed ID: 12599844
    [Abstract] [Full Text] [Related]

  • 38. Impact of lower achieved blood pressure on outcomes in hypertensive patients.
    Okin PM, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB.
    J Hypertens; 2012 Apr 27; 30(4):802-10; discussion 810. PubMed ID: 22343536
    [Abstract] [Full Text] [Related]

  • 39. Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study).
    Wachtell K, Palmieri V, Gerdts E, Bella JN, Aurigemma GP, Papademetriou V, Dahlöf B, Aalto T, Ibsen H, Rokkedal JE, Devereux RB.
    Am J Cardiol; 2010 Oct 01; 106(7):999-1005. PubMed ID: 20854964
    [Abstract] [Full Text] [Related]

  • 40. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
    Carr AA, Kowey PR, Devereux RB, Brenner BM, Dahlöf B, Ibsen H, Lindholm LH, Lyle PA, Snapinn SM, Zhang Z, Edelman JM, Shahinfar S.
    Am J Cardiol; 2005 Dec 01; 96(11):1530-6. PubMed ID: 16310435
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.